A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Inclusion Criteria: * A histopathologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction (GEJ) adenocarcinoma which is metastatic or locally advanced and unresectable. A participant with esophageal cancer is not eligible. * Not have received prior first-line systemic chemotherapy for locally advanced and unresectable and/or metastatic disease. Participants whose disease has progressed after \>6 months following the last dose of systemic treatment in the adjuvant/neoadjuvant setting are eligible. * Measurable or nonmeasurable, but evaluable, disease, determined using guidelines in Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 at the time of enrollment. * The participant has adequate organ function. * Resolution to Grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version \[v\]4.03) of all clinically significant toxic effects of prior locoregional therapy, surgery, or other anticancer. * Female participants of childbearing potential must have a negative serum or urinary pregnancy. Have an estimated life expectancy of ≥12 weeks in the judgment of the investigator. Exclusion Criteria: * A significant bleeding disorder, vasculitis, or had a significant bleeding episode from the gastrointestinal tract within 12 weeks prior to enrollment. * Uncontrolled arterial hypertension, despite standard medical management. * A serious or nonhealing wound or peptic ulcer or bone fracture at enrollment. * Undergone major surgery within 28 days prior to enrollment, or subcutaneous venous access device (reservoir) placement within 7 days prior to enrollment. * Radiation therapy within 14 days prior to enrollment. * Received any previous systemic therapy (including investigational agents) targeting vascular endothelial growth factor (VEGF) or the VEGF receptor signaling pathways. * Cirrhosis at a level of Child-Pugh B (or worse); or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. * A serious illness or medical condition(s). * Pregnant or breastfeeding. * Dysphagia for oral medication. * Known allergy or hypersensitivity to any study treatment. * Human epidermal growth factor receptor (HER) 2 status of positive. * Received treatment within 28 days of the initial dose of study drug with an investigational product or non-approved use of a drug or device.